'Great Optimism' Over Complete Responses in dMMR Rectal Cancer
A small trial shows that patients with locally advanced rectal cancer and deficient mismatch repair tumors respond remarkably well to neoadjuvant PD-1 blockade with dostarlimab.
Medscape Medical News
source https://www.medscape.com/viewarticle/975062?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/975062?src=rss
Comments
Post a Comment